Total medical devices industry cross border venture financing deals worth $1.7bn were announced globally in Q3 2022, led by $223m venture financing of Cleerly, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 21.5% over the previous quarter and a drop of 44.7% when compared with the last four-quarter average, which stood at $3.04bn.
Comparing cross border deals value in different regions of the globe, North America held the top position, with total announced deals worth $1.14bn in the period. At the country level, the US topped the list in terms of deal value at $1.07bn.
In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of cross border venture financing deals activity in Q3 2022 was the US with 25 deals, followed by China with ten and Canada with eight.
In 2022, at the end of , cross border venture financing deals worth $1.7bn were announced globally in medical devices industry, marking an increase of 33.04% year on year.
Cross Border venture financing deals in medical devices industry in Q3 2022: Top deals
The top five cross border venture financing deals in medical devices industry accounted for 36.1% of the overall value during Q3 2022.
The combined value of the top five cross border venture financing deals stood at $608m, against the overall value of $1.7bn recorded for the quarter.
The top five medical devices industry cross border venture financing deals of Q3 2022 tracked by GlobalData were:
1) Breyer Capital, Cigna Ventures, DigiTx Partners, Fidelity Management & Research, Heartland Healthcare Capital, LRVHealth, Mirae Asset Capital, New Leaf Ventures, Novartis, Peter Thiel, Piper Sandler Merchant Banking, Sands Capital Management, T Rowe Price Associates, T. Rowe Price Investment Management and Vensana Capital’s $223m venture financing deal with Cleerly
2) The $110m venture financing of Orchestra BioMed by Medtronic, Perceptive Advisors, RTW Investments, SternAegis Ventures and Terumo
3) Emerson Collective (Emmerson Collective) and KIRKBI Invest’s $100m venture financing deal with Kerecis ehf
4) The $100m venture financing of JenaValve Technology by Andera Partners, Bain Capital Life Sciences, Cormorant Asset Management, Gimv, Innovatus Capital Partners, Peijia Medical, Pictet Alternative Advisors, Qatar Investment Authority, RMM Consulting Group, Valiance Advisors and Venture Incubator
5) Andera Partners, BioStar Capital, Deerfield Management Co, Fountain Healthcare Partners, Panakes Partners, RA Capital Management and Samba Tech’s $75m venture financing deal with Medical Microinstruments